title: Scleroderma: a treatable disease.
abstract: Many effective treatments for scleroderma have emerged in recent years, including bosentan, an endothelin receptor antagonist, and epoprostenol, a prostacyclin, both of which target vasoconstriction. Cyclophosphamide may soon be proven effective against interstitial lung disease.
authors.affiliation: Arthritis Center, Boston University School of Medicine, MA 02118, USA.
authors.forename: Joseph H
authors.initials: JH
authors.lastname: Korn
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D000077300:Bosentan; D006801:Humans; D011658:Pulmonary Fibrosis / Q000209:etiology; D012595:Scleroderma, Systemic / Q000150:complications / Q000503:physiopathology / Q000628:therapy*; D013449:Sulfonamides / Q000627:therapeutic use
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D013449:Sulfonamides; D000077300:Bosentan